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Summary 
Tolerance of monocytes/macrophages  to endotoxin  (lipopolysaccharide  [LPS]) can be induced 
both in vivo and in vitro by LPS itself.  Exposure to LPS,  even at a very low dose, induces a 
downregulation of cytokine response to a second high dose LPS challenge. To learn more about 
the unknown mechanisms of this phenomenon, we studied the role of antiinflammatory cytokines 
in this process. Preculture of human peripheral blood monocytes for 24 hours with low concen- 
trations of LPS induced hyporesponsiveness to high-dose LPS rechaUenge with respect to tumor 
necrosis factor (TNF) c~ and interleukin (IL) 10 but not IL-1RA production. These results sug- 
gest that  LPS tolerance  reflects  a functional  switch  of monocytes rather  than  a general  LPS 
hyporesponsiveness. IblO and transforming  growth factor (TGF) 31 showed additive effects in 
replacing LPS for induction of LPS hyporesponsiveness  in vitro. Additionally,  neutralizing anti-IL-10 
and anti-TGF-~ monoclonal antibodies prevented induction of LPS tolerance.  In vitro induced 
LPS tolerance looks like the ex vivo LPS hyporesponsiveness of monocytes from septic patients 
with fatal  outcome: downregulation  of LPS-induced TNF-oe and IL-10 production but not of 
IL-1RA secretion. LPS hyporesponsiveness in septic patients was preceded by expression of 11.-10 
at both  the mRNA  and protein level.  In  summary,  our data  suggests that  IL-10 and TGF-~ 
mediate the phenomenon of LPS tolerance in vitro and perhaps in vivo (septic patients),  too. 
M 
onocytes and macrophages are highly sensitive for LPS, 
reacting  on encounter  with even traces by synthesis 
of inflammatory  mediators.  Among  them,  a  network  of 
proinflammatory cytokines is of special  importance for the 
coordinated activation of the immune system in response to 
microbial invasion. When local infection develops into sepsis, 
a strong systemic reaction occurs, and cytokines normally re- 
stricted to areas of local injury can be detected systemically 
causing symptoms of septic shock (1). Although whole-body 
inflammation is frequently initiated by LPS, a single sublethal 
injection of LPS also renders the host temporarily refractory 
to subsequent LPS challenge as well as to other inflamma- 
tory stimuli. This phenomenon, referred to as endotoxin toler- 
ance may be at least partially due to a reduced capacity of 
monocytes/macrophages to synthesize cytokines upon reex- 
posure to LPS (2). The phenomenon of in vivo LPS desen- 
sitization has been reproduced in vitro using murine or human 
monocytes/macrophages (3-5). The mechanisms of LPS toler- 
ance are not clear so far.  Modulation  of LPS-binding  sites 
(CD14),  secretion  of inhibitory  mediators  by desensitized 
monocytes, and an altered intracellular  signaling have been 
discussed (3,  6-8). 
Antiinflammatory mediators such as I1.-10, TGF-B, or IL- 
1RA which are produced also by monocytes after LPS con- 
tact but with delayed kinetics, are thought to be important 
for downregulating  the inflammatory cascade,  and they are 
known to be protective in animal models of sepsis. We won- 
dered whether (a) the production of antiinflammatory medi- 
ators is also downregulated in LPS-tolerant monocytes; and 
(b) the secretion of antiinflammatory mediators, particularly 
IL-10 and TGF-3, may be involved in the induction of LPS 
hyporesponsiveness. 
We found I1.-10 to be also downregulated in the process 
of LPS desensitization, while production of IL-1RA was not 
significantly modified. Furthermore, our results indicate that 
IL-10 and TGF-~ are essential factors for the induction of LPS 
desensitization and that their action is sufficient to establish 
LPS hyporesponsiveness. Our in vitro model shows parallels 
to the properties of monocytes from patients suffering from 
gram-negative  sepsis  with  high late lethality. 
Materials and Methods 
Cell  Culture Techniques.  Human  PBMC  were  isolated  by 
Ficoll-Paque density gradient centrifugation  and were cultured at 
a density of 106 cells/m1 in RPMI-1640 supplemented with 10% 
(vol/vol) heat-inactivated FCS (both with "low endotoxin  certi- 
ficate" Biochrom KG, Berlin, Germany),  2 mM glutamine,  100 
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essentially  free of contaminating endotoxin as indicated by the 
Limulus assay (Coatest~;  Chromogenix AB, M61ndal,  Sweden) 
and the absence of spontaneous TNF-ol production (<15 pg/ml 
per 106 cells) by cultured human PBMC. LPS pretreatment in pri- 
mary culture was performed for 24 h in the presence of 200 pg/ml 
LPS from Esckerickia coli 055:B5 (Sigma Chemical Co., St. Louis, 
MO). After extensive washing,  cells were restimulated in secondary 
culture with 10 ng/ml LPS for a further 24 h before supernatants 
were  harvested.  Neutralizing  anti-TGF-fll-3  mAb  (Genzyme, 
Munich,  Germany)  and  anti-IL-10  mAb  19F1 (IgG1)  (kindly 
provided by Dr. J.  E. de Vries, DNAX Research Institute,  Palo 
Alto, CA) were added to some cultures as indicated. To simulate 
the induction of LPS desensitization,  cells were treated with recom- 
binant human TGF-~I (Biermann, Bad Nauheim, Germany) and 
IL-10 (kindly provided by Dr. de Vries) for 24 h at the indicated 
concentrations, washed extensively, and stimulated with 10 ng/ml 
LPS for a further 24 h. For quantification of TNF-c~ mRNA, sec- 
ondary culture was done in the presence or absence of 10 ng/ml 
LPSP for 5 h. 
Patients' PBMC were cultured in the presence or absence of 100 
ng/ml LPS for 24 h without preculture. In summary, 36 patients 
suffering from gram-negative sepsis (24 with E. coli and 12 with 
Pseudomonas species infection) at different stages  (early and late 
phases) were investigated. Sepsis developed on the basis of perito- 
nitis (n =  19), pancreatitis (n =  8), polytrauma (n =  8), and burn 
(n  =  1). On the basis of our recent studies (9-11),  the patients 
were divided into three subgroups according to their proportion 
of HLA-DR + monocytes in peripheral blood: <30%  (fatal out- 
come:  10 out of 12 patients), 30-45%  (fatal outcome: 6 out of 
12 patients),  )45%  (fatal outcome: 3 out of 12 patients).  The 
proportion of HLA-DR + CD14 + monocytes was determined by 
two-color flow cytometry as described  elsewhere (9,  10). 
Cytokine Assays.  Cytokine production was measured by ELISAs 
specific for TNF-o~ (Medgenix, Ratingen, Germany), II.-10 (Cyto- 
screen~; Laboserv, Giessen, Germany), and IL-1RA (Quantikine~; 
Biermann). 
Quantification ofmRNA Level.  Quantitative PCR analyses were 
performed as described in detail elsewhere (12). Briefly, total RNA 
was extracted from PBMC. Quantification of TNF-o~ and IL-IO 
cDNA derived from this RNA was carried out using multispecific 
control fragments as an internal standard for competitive PCR (12). 
First, the various cDNA samples to be compared were equilibrated 
according to their glyceraldehyde-3-phosphate-dehydrogenase cDNA 
content. Then, the relative concentration of TNF-c~ or IL-10  cDNA 
in each sample  was estimated from the concentration of control 
fragment  DNA  that  achieved  equilibrium  between  its  own 
amplification and that of the target cDNA.  The concentrations 
were expressed  in arbitrary units (AU). One AU was defined as 
the lowest concentration of control fragment that yielded a detect- 
able amplification product given the TNF-a or IL-IO primer pair 
and PCR conditions used (1 AU  =  10-9-fold dilution of control 
fragment, corresponding to ~30 molecules)  (12). 
Results 
Regulation  of  Cytokine  Production  in  LPS  Desensitiza- 
tion.  Stimulation of PBMC with LPS led to a dose-dependent 
induction of TNF-cr, IL-1RA, and IL-10 during the first 24 
h  of culture (primary culture) (data not shown).  As shown 
in Fig. 1, presence of LPS during primary culture diminished 
the capacity to produce both the proinflammatory cytokine 
TNF-ot and the antiinflammatory mediator IL-10 during the 
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Figure 1.  LPS desensitization diminishes TNF-c~ and IL-10 synthesis 
but not IL-1RA synthesis. 1 million PBMC/ml were treated with the in- 
dicated amounts of LPS for 24 h. After extensive washing, cells were re- 
stimulated with 10 ng/ml LPS for a further 24 h. Supernatants were har- 
vested and  cytokines were determined by specific ELISAs. (A)  One 
representative dose-response curve out of four independent experiments 
is shown. (B) Results of independent experiments (n  =  7 for TNF-~, 
n = 11 for IL-10 and IL-1RA) using different donors are summarized. 
Statistical analysis was done by Mann-Whitney-Wilcoxon  test. 
secondary culture with LPS (second 24 h).  The degree of 
inhibition depended on the amount of LPS used in primary 
culture.  Fig.  1 B  shows  great  interindividual  and  interex- 
perimental variability in the amounts of TNF-cg and IL-10 
synthesized by non-LPS-pretreated cells and  the profound 
downregulation of production after pretreatment with 200 
pg/ml LPS (p <~0.01, Mann-Whitney-Wilcoxon test).  Inde- 
pendent of the highly variable capacity of non-LPS-pretreated 
cells to produce these two cytokines, all but one of the LPS- 
pretreated cultures were desensitized to the same degree. In 
contrast to the results obtained for TNF-o~ and IL-10,  syn- 
thesis of IL-1RA in LPS-pretreated cells was not significantly 
influenced (Fig.  1).  Essentially the same pattern of regula- 
tion was found for different lengths of secondary culture (4-48 
h) and for varying amounts of LPS (1-100 ng/ml)  used for 
restimulation (data not shown).  The high variability in the 
amounts of IL-1RA produced in non-LPS-pretreated ceils is 
very well conserved in LPS-pretreated cells (Fig.  1 B).  Al- 
though in rare cases a marginal reduction of IL-1RA produc- 
tion was found, no significant difference or even a consider- 
able priming  was  seen in  most experiments. 
Recently, it has been  shown  that  LPS desensitization is 
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reproduced this result for TNF-ot (data not shown) and semi- 
quantified mRNA levels. Untreated PBMC contained some 
TNF-ot mRNA that was halved in LPS-pretreated cells after 
LPS-free  secondary culture.  Non-LPS-pretreated cells re- 
sponded to  LPS in secondary culture by increasing their 
amount of TNF-oe mRNA about fivefold, while rechallenge 
of LPS-pretreated cells did not increase their TNF-ot mRNA. 
Prevention of  LPS Desensitization by Neutralization of  Endog- 
enous TGF-fl and IL,  IO.  Requirement of active protein bio- 
synthesis for establishment of the desensitized  stage (5, 7, 
13) caused us to study whether cytokines, particularly IL-10 
and TGF-3, known for their cytokine synthesis-inhibiting 
activity and produced during primary culture, may be in- 
volved in downregulation of TNF-ot production after LPS 
rechallenge  (14, 15). Neutralization of TGF-/3 during pri- 
mary culture led to a slightly increased TNF-ot synthesis in 
secondary culture compared with desensitized control cells 
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Figure 2.  Neutralization of Ibl0 and TGF-~ during primary culture 
prevents establishment of LPS desensitization, while addition of IL-10 and 
TGF-3I induces LPS hyporesponsiveness. PBMC were cultured for 24 h 
in the presence (A) or absence (/3 and C) of 200 pg/ml LPS and neu- 
tralizing anti-TGF-3 and anti-IL-10 mAbs (A) or TGF-31 and ILl0 (B 
and C) as indicated. Controls (naive cells) were cultured without LPS. 
After washing, cells were restimulated with 10 ng/ml LPS for a further 
24 h. Cytokines in supernatants were determined by ELISAs. Amounts 
of TNF-ct and IL-10 produced in secondary culture by naive cells from 
different donors in four independent experiments ranged from 1,346 to 
6,250 pg/ml and 152 to 1,956 pg/ml, respectively. The relative produc- 
tion of TNF-cr and IL-10 (mean and SE) in comparison to that of naive 
PBMC is shown. 
(Fig. 2 A). Blocking of endogenous II,-10 by a neutralizing 
mAb was even more effective, leading to a fourfold increased 
TNF-ot secretion. However, neutralization of both cytokines 
was necessary to prevent completely the LPS-induced LPS 
tolerance (Fig. 2 A). Addition of these mAbs to LPS-free pri- 
mary cultures caused no modification of TNF-ct expression 
in secondary cultures, supporting the specifidty of their effects 
(data not shown). Furthermore, LPS desensitization was not 
prevented by addition of these mAbs to secondary culture 
(data not shown), thus excluding the possibility of remaining 
traces of antibodies from primary culture being responsible 
for the elevated TNF-oe synthesis. 
Mimicry of LPS Desensitization by TGF-fll and lL10.  Next, 
we wondered whether TGF-3 and II,-10 are essential factors 
for establishment of LPS desensitization or if these cytokines 
could even replace LPS during primary culture. Cells treated 
for 24 h with IL-10 and TGF-31,  washed extensively,  and 
stimulated with LPS showed a strongly diminished IL-10 and 
TNF-oe synthesis similar to the level reached by LPS desen- 
sitization (Fig.  2, B and C). IL-10 pretreatment of mono- 
cytes inhibited significantly  the production of both TNF-ol 
and IL-10. While TGF-31 by itself preferentially downregu- 
lated IL-10 expression, IL-10 more strongly inhibited TNF-c~ 
production. Regarding IL-10 production, TGF-3 and IL-10 
acted in an additive  manner. 
LPS Hyporesponsiveness in Septic Disease.  Recently, we and 
others (10, 11, 16) described an impaired capacity of mono- 
cytic LPS-induced TNF-ol, IL-13, and IL-6 production in a 
subgroup of septic patients with high lethality. The func- 
tional deactivation of patients' monocytes was closely related 
to the downregulation of monocytic HLA-DR antigen ex- 
pression  (10, 11). 
To test the possibility of a relationship between "classical" 
LPS tolerance and the phenomenon of LPS hyporesponsive- 
hess in patients suffering from fatal sepsis, we looked for 
similarities between both phenomena. As shown in Fig. 3, 
the 24-h supernatants of monocytes from patients with low 
monocytic HLA-DR expression (and high lethality) contained 
much lower amounts of TNF-ce and IL-10 compared with 
control subjects,  while their IL-1RA content was not sig- 
nificantly  different. 
Concerning IL-10, in septic patients expressing low or in- 
termediate levels of monocytic HLA-DR antigen (<45% 
HLA-DR +  monocytes), two distinct functional states  of 
monocytes were observed: (a) Many of these patients (19 out 
of 24) showed significant IL-10 production within 4 h after 
LPS stimulation in vitro (data not shown), while normally 
IL-10 is not detected before 10-12 h. This suggests in vivo 
priming for early onset of IL-10 secretion.  This view is sup- 
ported further by the detection of IL-10 mRNA in freshly 
isolated monocytes in 18 out of 24 patients with <45% HLA- 
DR + monocytes. In contrast, Ibl0 mRNA was rarely  (3 
out of 12) or not (0 out of 12) detectable in septic patients 
with >45%  HLA-DR + monocytes or healthy donors, re- 
spectively. Thus, the early secretion of IL-10 after LPS stimu- 
lation may result in downregulation of TNF-ot synthesis and 
self-limiting IL-IO  production, which was measured 24 h later. 
(b) The absence of early IL-10 production and the low levels 
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Figure 3.  Downregulation  of TNF-ot and ILl0 but not of IL-1RA 
production  by monocytes  from patients  with fatal  sepsis. PBMC from 36 
patients suffering  from  gram-negative  sepsis were stimulated  for 24 h with 
100 ng/ml LPS. Cytokine  concentrations  in supernatants  were determined 
by specific  ELISAs.  Septic  patients were divided  into three groups (12 pa- 
tients in each group) according  to their monocytic  HLA-DR  antigen  ex- 
pression (healthy  donors: 80-95% [ ['--]]). Low HLA-DR antigen ex- 
pression (group I:  HLA-DR+CD14  +  <30% [~]  or  group II: 
HLA-DR+CD14  * 30-45% [!II11]) was related to high Lethality  (10 out 
of 12 = 84% and 6 out of 12 = 50%, respectively),  while  relatively  high 
HLA-DR antigen expression (group 1II: HLA-DR+CD14  + >45% 
[IIIIN1]) was found in the patients' group with low lethality  (3 out of 
12  =  25%). Mean values and SE are shown. *p <0.01 vs probands; 
￿9  *p <0.05 vs probands. 
of both IL-10 and TNF-ot after 24 h in 5 out of 24 patients 
indicate a "completely desensitized" state. This suggests that 
desensitization had occurred already in vivo. 
Discussion 
Excessive production of TNF-a and other proinflamma- 
tory mediators after stimulation by LPS may result in fever, 
intravascular coagulation, and lethal septic shock. An efficient 
way of  preventing the whole-body inflammation  may be desen- 
sitization of monocytes/macrophages to LPS. We have fur- 
ther characterized the phenomenon of LPS tolerance and 
analyzed the mechanisms involved in the induction of desen- 
sitization. Our results may be summarized as follows: (a) In 
addition to the well-established downregulation of TNF-ot 
production, LPS tolerance also switched off IL-10 produc- 
tion, while secretion of IL-1RA, another antiinflammatory 
cytokine, was not significantly  influenced. This suggests that 
LPS tolerance is not a phenomenon of general hyporespon- 
siveness. (b) ILl0 seems to be an essential endogenous medi- 
ator that induces the state of LPS tolerance because  IL-10 
replaced LPS and anti-IL-10 mAb prevented the LPS-mediated 
induction of LPS tolerance in an additive manner with TGF- 
/31 and anti-TGF-/8  mAb, respectively.  (c) Fatal sepsis is as- 
sociated with a state of monocytic LPS hyporesponsiveness 
similar to the phenomenon of LPS tolerance, i.e., normal ex- 
pression of IL-1RA and reduced synthesis of TNF-c~ and ILIO. 
Several reports on soluble factors mediating LPS desensiti- 
zation indirectly support our data on the involvement of IL-IO 
in this process (6, 7). Inhibition of cyclooxygenase by indo- 
methacin was found to interfere with establishment of LPS 
desensitization, while on the other hand, PGEz  (a  major 
product of this pathway and known to negatively regulate 
TNF-c~ synthesis) on its own was unable to induce hypore- 
sponsiveness (7).  Recently, we reported that PGE2 or pro- 
stacyclin considerably increased the LPS-induced ILl0 secre- 
tion, while it had no effect in the absence of LPS (17). Thus, 
the inhibition of LPS desensitization by indomethacin could 
be mediated indirectly via diminished IL-10 production. 
Concerning the central position of IL-10 in the regulatory 
network leading to LPS desensitization, it is surprising to 
find IL-10 as downregulated as TNF-c~. However, inhibition 
of IL-10 production by itself is well established  (14). Obvi- 
ously, IL-10 is essential for induction but not for maintenance 
of LPS hyporesponsiveness  because neutralization of ILol0 in 
primary but not in secondary culture reestablished  TNF-ot 
expression.  IL-10 seems to mediate its long-lasting effect on 
TNF-oe expression via induction of another protein since its 
downstream signaling is inhibited by cycloheximide (15). 
The mechanism of TGF-3 action on LPS desensitization 
is not so dear. Whereas neutralization of endogenous TGF-3 
improved TNF-ot secretion after LPS pretreatment, addition 
of  exogenous TGF-31 alone to naive monocytes did not induce 
LPS hyporesponsiveness.  This observation suggests the exis- 
tence of endogenously produced TGF-/3 that is not sufficient 
to induce LPS desensitization in the absence of IL-10. In fact, 
PBMC constitutively express TGF-/3 mRNA (data not shown). 
The induction of LPS desensitization is a highly organized 
process that involves de novo protein synthesis (7). But even 
the desensitized  monocyte/macrophage reflects not simply 
a deactivated cell since it is able to produce regulatory medi- 
ators  such as G-CSF (5)  or IL-1RA (this work). 
It is well established that inflammatory mediators, partic- 
ularly TNF-c~,  play an important role in the pathogenesis 
of septic  disease (1). However, the course of septic  disease 
seems to reflect a biphasic inflammatory  response. The initial 
hyperinflammatory phase,  which induces shock, etc., may 
switch into a hypoinflammatory state.  In fact, in the sub- 
group of patients with strongly reduced proportions of HLA- 
DR + monocytes, we observed diminished TNF-ot and IL- 
l0 production after LPS stimulation, while IL-1RA secretion 
was not influenced. In light of our analogous results on in 
vitro--desensitized PBMC, it is tempting to speculate on similar 
mechanisms for both phenomena. The first contact with LPS 
should lead to induction of early inflammatory and delayed 
antiinflammatory  cytokine production. After the antiinflam- 
matory response,  a long-lasting state of hyporesponsiveness 
may be established. 
Induction of LPS tolerance has been suggested as an alter- 
native therapeutic strategy for septic disease. Animal experi- 
ments (18) and recent human studies on the effects of single 
low dose LPS administration (19, 20) have demonstrated the 
efficacy of such an approach. To prevent undesired side effects, 
the use of modified nontoxic LPS analogues was postulated 
as an alternative strategy (5), Our data suggest that IL-10  may 
replace LPS or LPS derivatives for induction of LPS tolerance 
in vivo. 
IL-10 has  turned out  to  be  a  potent  antiinflammatory 
1890  Role of IL-10 and TGF-3 in Endotoxin Desensitization cytokine, and it has protected animals against lethal LPS ad- 
ministration (21). However, our data suggest that timing of 
IL-10 administration will strongly influence its eflacacy. Ad- 
ministration before onset of septic shock may be successful, 
but it will probably fail in established  sepsis, as have other 
antiinflammatory  therapeutic strategies (e.g., anti-TNF mAb) 
that worked well in animal models but failed in controlled 
human trials (22-24). The reason for this discrepancy might 
be that many patients who survived the acute phase of septic 
shock because of modern intensive care died from multiple- 
organ failure and persistent infections weeks or even months 
later in the intensive care unit. Late mortality in septic dis- 
ease is associated with a low level of monocytic HLA-DR 
expression and LPS hyporesponsiveness (Fig. 3) (10, 11). The- 
oretically, IL-10 is not expected to have any protective effect 
on this situation. On the other hand, immunostimulatory 
strategies (such as administration of IFN-3', GM-CSF, anti- 
IL-10 mAh, and inhibitors of PGE synthesis)  may be useful 
to break monocytic hyporesponsiveness during the late (hypo- 
inflammatory) phase but are dangerous during the early (hyper- 
inflammatory) phase because  they are  able to magnify the 
overshooting inflammatory reaction. 
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